Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer — Stella

Recruiting

Back to Breast Cancer Female trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(3 sites)

Canada

Hôpital Maisonneuve-Rosemont, Montreal, Quebec

Centre hospitalier de l'Université de Montréal, Montreal, Quebec

Jewish General Hospital, Montreal, Quebec

Key details

Sponsor

Jewish General Hospital

Collaborators

Quebec Breast Cancer Foundation

Enrollment target

~98 participants

Started

March 2021

Primary completion

July 2026

Age range

18 Years and older

Sex

Female only

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov